共 50 条
- [31] Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Neoptolemos, John P.Palmer, DanielGreenhalf, WilliamGhaneh, PaulaJackson, RichardEvans, AnthonyShaw, VictoriaWadsley, JonathanValle, Juan W.Wasan, HarpreetFalk, StephenCunningham, DavidCoxon, Fareeda Y.Ross, Paul J.Wadd, NickHickish, TamasCostello, EithneCampbell, FionaRawcliffe, CharlotteMiddleton, Gary William
- [32] ESPAC-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal AdenocarcinomaPANCREAS, 2016, 45 (10) : 1529 - 1529Neoptolemos, J. P.Palmer, D.Ghaneh, P.Valle, J.Cunningham, D.Wadsley, J.Meyer, T.Anthoney, A.Glimelius, B.Falk, S.Lind, P.Izbicki, J.Middleton, G.Ross, P.Wasan, H.McDonald, A.Crosby, T.Psarelli, E.Hammel, P.Buechler, M. W.
- [33] Regional hyperthermia (RHT) combined with gemcitabine (GEM) plus cisplatin (CIS) in patients with GEM-refractory advanced pancreatic cancer: Results of the ESHO phase II trialJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Tschoep, K. E.Boeck, S.Berger, F.Maier, V.Abdel-Rahman, S.Kuhlencordt, M.Salat, C.Schmidt, M.Heinemann, V.Issels, R. D.
- [34] RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)Ko, Andrew H.Murphy, Patrick B.Peyton, James D.Shipley, DiannaAl-Hazzouri, AhmedRodriguez, Frank A.Womack, Mark S.Xiong, Henry Q.Waterhouse, David M.Tempero, Margaret A.Bendell, Johanna C.
- [35] A randomized, double-blind, multicenter phase II AIO trial with Gemcitabine plus Sorafenib versus Gemcitabine plus placebo in patients with chemo-naive advanced or metastatic biliary tract cancer: first safety and efficacy dataONKOLOGIE, 2011, 34 : 217 - 217Moehler, M.Kanzler, S.Schimanski, C. C.Woerns, M. A.Denzer, U.Kolligs, F.Ebert, M.Distelrath, A.Zeuzem, S.Lammert, F.Geissler, M.Lohse, A.Dollinger, M.Lindig, U.Duerr, M.Lubomierski, N.Kabisch, M.Schadmand-Fischer, S.Galle, P. R.
- [36] Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa): Design of CA180-375, a placebo-controlled, randomized, double-blind phase II trialJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Evans, T. R. JeffryVan Cutsem, EricMoore, Malcolm J.Purvis, Joseph D.Strauss, Lewis C.Rock, Edwin P.Lee, JenniferLin, ChihcheRosemurgy, AlexanderArena, Francis P.Gara, MichelleArmstrong, ElizabethO'Dwyer, Peter J.
- [37] Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancerANNALS OF ONCOLOGY, 2008, 19 (02) : 340 - 347Boeck, S.Hoehler, T.Seipelt, G.Mahlberg, R.Wein, A.Hochhaus, A.Boeck, H. -P.Schmid, B.Kettner, E.Stauchlo, M.Lordick, F.Ko, Y.Geissler, M.Schoppmeyer, K.Kojouharoff, G.Golf, A.Neugebauer, S.Heinemann, V.
- [38] A multicenter, randomized, double-blind trial of prednisolone plus azathioprine versus prednisolone plus placebo in myasthenia gravisNEUROLOGY, 1996, 46 (02) : 32001 - 32001Palace, JNewsomDavis, JLecky, B
- [39] Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic CancerJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1475 - 1481Borad, Mitesh J.Reddy, Shantan G.Bahary, NathanUronis, Hope E.Sigal, DarrenCohn, Allen L.Schelman, William R.Stephenson, Joe, Jr.Chiorean, E. GabrielaRosen, Peter J.Ulrich, BrianDragovich, TomislavDel Prete, Salvatore A.Rarick, MarkEng, ClarenceKroll, StewRyan, David P.
- [40] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trialJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)Tehfe, Mustapha AliDowden, Scot D.Kennecke, Hagen F.El-Maraghi, Robert HassanLesperance, BernardCouture, FelixLetourneau, RichardPenenberg, Darryl NeilRomano, AlfredoVon Hoff, Daniel D.